Express News | Vivani Medical Shares up 5.6% on Plans to Begin Human Trial for Obesity Implant
Express News | Vivani Medical Inc: Expects to Initiate First Clinical Study Supporting Npm-115 Program in Q4 of 2024
Express News | EXCLUSIVE: Vivani Tells Benzinga 'The NPM-115 Clinical Program Will Consist of a Series of Studies Designed to Support the Development of Vivani's Miniature, 6-month GLP-1 NanoPortalTM Implant for Chronic Weight Management in Obese or Overweight Patients'
Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'Vivani Expects to Initiate the First Clinical Study Supporting the NPM-115 Program in the Fourth Quarter of 2024'
Express News | EXCLSUIVE: Vivani Medical Tells Benzinga Co. Provides Update On Clinical Development Plans For Miniature, Long-Term, GLP-1 Obesity Implant Program, NPM-115
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Maxim Group Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $8
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why GLP-1 Developer Vivani Medical's Stock Is Climbing
Vivani Medical (VANI) Stock Surge Following FDA Clearance
Express News | Vivani Medical Shares up 14% as US FDA Lifts Clinical Hold on Trial for Diabetes Treatment Implant
IVivani Medical Gets FDA Clearance to Start Trial of GLP-1 Implant for Diabetes
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED)
Express News | Vivani Medical Shares Are Trading Higher After the Company Announced the FDA Cleared the Investigational New Drug Application and Lifted the Clinical Hold on NPM-119
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for Npm-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'Study Will Represent First Clinical Application of NanoPortal, the Company's Proprietary, Implant Platform Technology'
Express News | EXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-119 Is Being Studied to Address Medication Non-adherence and Potentially Improve Tolerability Issues Associated With Oral and Injectable Type 2 Diabetes Medications'
Express News | EXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces FDA Clears Investigational New Drug Application And Lifts Clinical Hold For NPM-119, A Miniature Long-Term Subdermal GLP-1 Drug Implant
Insider Stock Buying Reaches US$751.8k On Vivani Medical